Meredith Ray
YOU?
Author Swipe
View article: Hydroxyurea utilization among individuals with sickle cell disease in Tennessee: a pooled analysis of claims data
Hydroxyurea utilization among individuals with sickle cell disease in Tennessee: a pooled analysis of claims data Open
Importance Hydroxyurea reduces severe disease among individuals living with sickle cell disease (SCD). These individuals experience high acute care utilization, but the associations between patterns of hydroxyurea utilization and healthcar…
View article: Implementing and retaining a large-scale technology-mediated cohort to study HIV incidence and PrEP uptake among vulnerable cisgender men as well as transgender individuals in the United States, the Together 5000 cohort
Implementing and retaining a large-scale technology-mediated cohort to study HIV incidence and PrEP uptake among vulnerable cisgender men as well as transgender individuals in the United States, the Together 5000 cohort Open
HIV remains a significant public health concern requiring innovative solutions. Widespread internet access and advancing health technologies (e.g., home-based HIV/STI testing) have often made research and intervention implementation more e…
View article: Statewide Academic Performance of High School Students With Sickle Cell Disease
Statewide Academic Performance of High School Students With Sickle Cell Disease Open
Purpose Among patients with sickle cell disease (SCD), poor academic attainment in adolescence is associated with a greater frequency of acute care visits and a poorer health‐related quality of life in adulthood. We compared the academic p…
View article: Reducing Smoking Requirements for Lung Screening to Address Health Disparities in a Community Cohort
Reducing Smoking Requirements for Lung Screening to Address Health Disparities in a Community Cohort Open
Importance Many individuals with lung cancer are not eligible for lung cancer screening (LCS). Race-based and sex-based differences in smoking patterns reduce the effectiveness of LCS criteria. Objective To assess the value of expanding LC…
View article: Transthoracic intracardiac line use and complications in the paediatric single ventricle population
Transthoracic intracardiac line use and complications in the paediatric single ventricle population Open
Transthoracic intracardiac lines provide a unique access point for postoperative monitoring and management in paediatric cardiothoracic surgeries, particularly within the single ventricle population where preserving vasculature is crucial …
View article: Dismantling Stereotypes About Being Top, Versatile, or Bottom: Sexual Minority Men’s Anal Sex Position Identity as It Relates to Attraction, Sexual Behavior, and Anthropomorphic Characteristics
Dismantling Stereotypes About Being Top, Versatile, or Bottom: Sexual Minority Men’s Anal Sex Position Identity as It Relates to Attraction, Sexual Behavior, and Anthropomorphic Characteristics Open
Many sexual minority men (SMM) use sex position self-labels, including "top," "bottom," "versatile," as well as combinations like "vers/top" and "vers/bottom" to describe engagement in anal intercourse. Despite the use of these labels, the…
View article: The American Transformative HIV Study: Protocol for a US National Cohort of Sexual and Gender Minority Individuals With HIV
The American Transformative HIV Study: Protocol for a US National Cohort of Sexual and Gender Minority Individuals With HIV Open
Background Sexual and gender minority (SGM) individuals represent 2%‐5% of the US population, yet continue to account for more than two-thirds of new HIV infections annually. Objective This study seeks to identify multilevel (ie, structura…
View article: Mental Health as a constituent of Human Rights: A study from the perspective of Healthcare Sector
Mental Health as a constituent of Human Rights: A study from the perspective of Healthcare Sector Open
Distress mental condition is defined as a detrimental human response that people generate due to unwanted pressures and complex situations at work place. Distress mental condition is a worldwide phenomenon and it is a common effect among v…
View article: Supplemental Table 1 from Prevalence of Epidermal Growth Factor Receptor and Programmed Death Ligand 1 Testing in a Population-Based Lung Cancer Surgical Resection Cohort from 2018 to 2022
Supplemental Table 1 from Prevalence of Epidermal Growth Factor Receptor and Programmed Death Ligand 1 Testing in a Population-Based Lung Cancer Surgical Resection Cohort from 2018 to 2022 Open
Supplemental Table 1: EGFR testing adjusting for rural or metropolitan hospitals and surgeon board certification as confounders in the parsimonious model.
View article: Supplemental Table 3 from Prevalence of Epidermal Growth Factor Receptor and Programmed Death Ligand 1 Testing in a Population-Based Lung Cancer Surgical Resection Cohort from 2018 to 2022
Supplemental Table 3 from Prevalence of Epidermal Growth Factor Receptor and Programmed Death Ligand 1 Testing in a Population-Based Lung Cancer Surgical Resection Cohort from 2018 to 2022 Open
Supplemental Table 3: Cohort Demographics by Testing Status in Eligible Persons.
View article: Supplemental Table 1 from Prevalence of Epidermal Growth Factor Receptor and Programmed Death Ligand 1 Testing in a Population-Based Lung Cancer Surgical Resection Cohort from 2018 to 2022
Supplemental Table 1 from Prevalence of Epidermal Growth Factor Receptor and Programmed Death Ligand 1 Testing in a Population-Based Lung Cancer Surgical Resection Cohort from 2018 to 2022 Open
Supplemental Table 1: EGFR testing adjusting for rural or metropolitan hospitals and surgeon board certification as confounders in the parsimonious model.
View article: Supplemental Table 4 from Prevalence of Epidermal Growth Factor Receptor and Programmed Death Ligand 1 Testing in a Population-Based Lung Cancer Surgical Resection Cohort from 2018 to 2022
Supplemental Table 4 from Prevalence of Epidermal Growth Factor Receptor and Programmed Death Ligand 1 Testing in a Population-Based Lung Cancer Surgical Resection Cohort from 2018 to 2022 Open
Supplemental Table 4: Cohort Characteristics by PDL1 Testing Status.
View article: Supplemental Figure 1 from Prevalence of Epidermal Growth Factor Receptor and Programmed Death Ligand 1 Testing in a Population-Based Lung Cancer Surgical Resection Cohort from 2018 to 2022
Supplemental Figure 1 from Prevalence of Epidermal Growth Factor Receptor and Programmed Death Ligand 1 Testing in a Population-Based Lung Cancer Surgical Resection Cohort from 2018 to 2022 Open
Supplemental Figure 1: Variation in EGFR and PDL1 testing in the Mid-south Quality of Surgical Resection cohort by Patient-, Provider-, and Institutional-level factors spanning a four year period including the first two years of FDA approv…
View article: Supplemental Table 2 from Prevalence of Epidermal Growth Factor Receptor and Programmed Death Ligand 1 Testing in a Population-Based Lung Cancer Surgical Resection Cohort from 2018 to 2022
Supplemental Table 2 from Prevalence of Epidermal Growth Factor Receptor and Programmed Death Ligand 1 Testing in a Population-Based Lung Cancer Surgical Resection Cohort from 2018 to 2022 Open
Supplemental Table 2: Cohort Characteristics by EGFR Testing Status.
View article: Data from Prevalence of Epidermal Growth Factor Receptor and Programmed Death Ligand 1 Testing in a Population-Based Lung Cancer Surgical Resection Cohort from 2018 to 2022
Data from Prevalence of Epidermal Growth Factor Receptor and Programmed Death Ligand 1 Testing in a Population-Based Lung Cancer Surgical Resection Cohort from 2018 to 2022 Open
Background:Biomarker-directed therapy requires biomarker testing. We assessed the patterns of epidermal growth factor receptor (EGFR) and programmed death ligand 1 (PDL1) testing in a non–small cell lung cancer (NSCLC) resection cohort. We…
View article: Supplemental Methods 1 from Prevalence of Epidermal Growth Factor Receptor and Programmed Death Ligand 1 Testing in a Population-Based Lung Cancer Surgical Resection Cohort from 2018 to 2022
Supplemental Methods 1 from Prevalence of Epidermal Growth Factor Receptor and Programmed Death Ligand 1 Testing in a Population-Based Lung Cancer Surgical Resection Cohort from 2018 to 2022 Open
Supplemental Methods 1: Standard Operating Procedure. Molecular Data Entry.
View article: Supplemental Table 5 from Prevalence of Epidermal Growth Factor Receptor and Programmed Death Ligand 1 Testing in a Population-Based Lung Cancer Surgical Resection Cohort from 2018 to 2022
Supplemental Table 5 from Prevalence of Epidermal Growth Factor Receptor and Programmed Death Ligand 1 Testing in a Population-Based Lung Cancer Surgical Resection Cohort from 2018 to 2022 Open
Supplemental Table 5: EGFR and PDL1 testing adjusting for rural or metropolitan hospitals.
View article: Supplemental Table 3 from Prevalence of Epidermal Growth Factor Receptor and Programmed Death Ligand 1 Testing in a Population-Based Lung Cancer Surgical Resection Cohort from 2018 to 2022
Supplemental Table 3 from Prevalence of Epidermal Growth Factor Receptor and Programmed Death Ligand 1 Testing in a Population-Based Lung Cancer Surgical Resection Cohort from 2018 to 2022 Open
Supplemental Table 3: Cohort Demographics by Testing Status in Eligible Persons.
View article: Supplemental Table 5 from Prevalence of Epidermal Growth Factor Receptor and Programmed Death Ligand 1 Testing in a Population-Based Lung Cancer Surgical Resection Cohort from 2018 to 2022
Supplemental Table 5 from Prevalence of Epidermal Growth Factor Receptor and Programmed Death Ligand 1 Testing in a Population-Based Lung Cancer Surgical Resection Cohort from 2018 to 2022 Open
Supplemental Table 5: EGFR and PDL1 testing adjusting for rural or metropolitan hospitals.
View article: Supplemental Table 2 from Prevalence of Epidermal Growth Factor Receptor and Programmed Death Ligand 1 Testing in a Population-Based Lung Cancer Surgical Resection Cohort from 2018 to 2022
Supplemental Table 2 from Prevalence of Epidermal Growth Factor Receptor and Programmed Death Ligand 1 Testing in a Population-Based Lung Cancer Surgical Resection Cohort from 2018 to 2022 Open
Supplemental Table 2: Cohort Characteristics by EGFR Testing Status.
View article: Supplemental Figure 1 from Prevalence of Epidermal Growth Factor Receptor and Programmed Death Ligand 1 Testing in a Population-Based Lung Cancer Surgical Resection Cohort from 2018 to 2022
Supplemental Figure 1 from Prevalence of Epidermal Growth Factor Receptor and Programmed Death Ligand 1 Testing in a Population-Based Lung Cancer Surgical Resection Cohort from 2018 to 2022 Open
Supplemental Figure 1: Variation in EGFR and PDL1 testing in the Mid-south Quality of Surgical Resection cohort by Patient-, Provider-, and Institutional-level factors spanning a four year period including the first two years of FDA approv…
View article: Supplemental Table 4 from Prevalence of Epidermal Growth Factor Receptor and Programmed Death Ligand 1 Testing in a Population-Based Lung Cancer Surgical Resection Cohort from 2018 to 2022
Supplemental Table 4 from Prevalence of Epidermal Growth Factor Receptor and Programmed Death Ligand 1 Testing in a Population-Based Lung Cancer Surgical Resection Cohort from 2018 to 2022 Open
Supplemental Table 4: Cohort Characteristics by PDL1 Testing Status.
View article: Supplemental Methods 1 from Prevalence of Epidermal Growth Factor Receptor and Programmed Death Ligand 1 Testing in a Population-Based Lung Cancer Surgical Resection Cohort from 2018 to 2022
Supplemental Methods 1 from Prevalence of Epidermal Growth Factor Receptor and Programmed Death Ligand 1 Testing in a Population-Based Lung Cancer Surgical Resection Cohort from 2018 to 2022 Open
Supplemental Methods 1: Standard Operating Procedure. Molecular Data Entry.
View article: Data from Prevalence of Epidermal Growth Factor Receptor and Programmed Death Ligand 1 Testing in a Population-Based Lung Cancer Surgical Resection Cohort from 2018 to 2022
Data from Prevalence of Epidermal Growth Factor Receptor and Programmed Death Ligand 1 Testing in a Population-Based Lung Cancer Surgical Resection Cohort from 2018 to 2022 Open
Background:Biomarker-directed therapy requires biomarker testing. We assessed the patterns of epidermal growth factor receptor (EGFR) and programmed death ligand 1 (PDL1) testing in a non–small cell lung cancer (NSCLC) resection cohort. We…
View article: Factors associated with PrEP‐era HIV seroconversion in a 4‐year U.S. national cohort of <i>n</i> = 6059 sexual and gender minority individuals who have sex with men, 2017−2022
Factors associated with PrEP‐era HIV seroconversion in a 4‐year U.S. national cohort of <i>n</i> = 6059 sexual and gender minority individuals who have sex with men, 2017−2022 Open
Introduction Community‐based cohort studies of HIV seroconversion can identify important avenues for enhancing HIV prevention efforts in the era of pre‐exposure prophylaxis (PrEP). Within individuals, one can assess exposure and outcome va…